Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Richard Baird

Has grant

Clinical Research Professor in Breast Cancer Therapeutics

University of Cambridge

United Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United Kingdom

Recent Grants

Grant: Close

Building Data Rich Clinical Trials

Open Date: 2021-02-01

Close Date: 2025-01-31

Grant: Close

NEO-RT: Pre-operative breast intensity modulated radiotherapy in patients receiving neo-adjuvant hormonal treatment for breast cancer

Open Date: 2017-01-01

Close Date: 2019-12-31

Grant: Close

PIONEER: Randomised Phase II Clinical Trial Pioneer Pre-Operative Window Study Of Letrozole Plus PR Agonist [Megace] Versus Letrozole Alone In Post-Menopausal Patients With ER-Positive Breast Cancer

Open Date: 2016-07-01

Close Date: 2020-10-01

Grant: Close

CRUK/15/010:plasmaMATCH:A multiple parallel cohort,non-randomised,open label,multicentre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening

Open Date: 2015-09-01

Close Date: 2021-08-31

Grant: Close

CRUK/12/047: Randomised phase 2 study of afatinib penetration into cerebral metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy (CamBMT1) (jointly funded by The Brain Tumour Charity)

Open Date: 2013-05-01

Close Date: 2016-10-31

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (29)

Pavel Mozgunov

Programme Leader Track

University of Cambridge

UNITED KINGDOM

Richard Baird

Research Interests

Make your next move.

Explore related searches

Recent Grants

Articles (20)

Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial

Modern Clinical Trials: Seamless Designs and Master Protocols

Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study

Key considerations for window of opportunity trials and preoperative endocrine therapy in breast cancer

The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial

Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1

SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy

Real-time cell viability monitoring for high-throughput drug screening using tumor xenograft-derived cells.

PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2− Breast Cancer: Clinical and Circulating Tumor DNA Results

Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Collaborative framework on responsible AI in LLM-driven CDSS for precision oncology leveraging real-world patient data

Results from SERENA-1 Parts K/L: A Phase 1 study of the next-generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) in combination with ribociclib in women with ER-positive, HER2 negative advanced breast cancer

Using circulating tumor DNA as a novel biomarker of efficacy for dose-finding designs in oncology

Cancer Core Europe: Leveraging Institutional Synergies to Advance Oncology Research and Care Globally

Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment.

A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.

Adaptive enrichment trial designs using joint modelling of longitudinal and time-to-event data.

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results.

Collaborators (29)

Pavel Mozgunov

Theresa Willem

Karen Pinilla Alba

Raoul Charles Coombes

Adam Brufsky

Raquel Perez-Lopez

Haiyan Zheng

Simak Ali

Jean Abraham

Judith Balmaña

Jennifer Diamond

Henrik Lindman

Piotr J. Wysocki

Laura Biganzoli

Alejandra Bruna

Elgene Lim

Stuart McIntosh

Carlo Palmieri

Peter Schmid

Robertus De Bruin

Kyung Hae Jung

Zahi I Mitri

Steven Hargreaves

Cinzia Brunelli

Giampaolo Bianchini

Erica Mayer

Christos Vaklavas

Belinda Kingston

Rebecca Burrell

Make your next move.